{"hands_on_practices": [{"introduction": "A virus's structure is a marvel of biological engineering, built from repeating protein subunits into a highly stable and symmetric container. This exercise delves into the stoichiometry of the adenovirus capsid, asking you to connect the number of individual protein monomers to the architecture of the complete virion. By performing this calculation and reasoning about its consequences, you will gain a deeper appreciation for how molecular composition dictates crucial viral properties like physical stability and interaction with the host immune system [@problem_id:4603459].", "problem": "Adenoviruses possess an icosahedral capsid built predominantly from the trimeric structural protein hexon. Each hexon is a trimer formed by three identical monomeric subunits. An intact adenovirus virion contains a lattice of hexon trimers arranged over its facets, while distinct penton complexes occupy the vertices. In structural virology, oligomerization stoichiometry is a central concept for connecting subunit counts to capsid architecture, and epitope multiplicity to antigen recognition. Parvovirus B19 (B19V), by contrast, has a smaller $T=1$ icosahedral capsid composed of repeated capsid proteins, leading to fewer copies of any given epitope on the virion surface.\n\nAssume an adenovirus virion contains $240$ hexon trimers and that each hexon trimer comprises $3$ identical monomers. Using fundamental stoichiometric reasoning about oligomeric complexes, determine the total number of hexon monomers per adenovirus virion. Then, starting from first principles about multivalency, cooperative interactions in lattices, and epitope copy number, explain qualitatively how this stoichiometry is expected to influence capsid stability and antigenic exposure compared to a smaller icosahedral virus such as Parvovirus B19 (B19V), which arranges its capsid proteins in a $T=1$ lattice with approximately $60$ subunits.\n\nReport the total monomer count as a unitless number. No rounding is required; provide the exact integer. Your qualitative reasoning should be logically grounded in the definitions above and general principles of multivalency and lattice stabilization, without assuming specific numerical binding constants or providing shortcut formulas for the calculation.", "solution": "The problem statement is evaluated for validity according to the specified criteria.\n\n### Step 1: Extract Givens\n- An adenovirus virion contains $240$ hexon trimers.\n- Each hexon trimer comprises $3$ identical monomers.\n- Parvovirus B19 (B19V) has a $T=1$ icosahedral capsid.\n- A $T=1$ lattice is composed of approximately $60$ subunits.\n- The task is to determine the total number of hexon monomers in one adenovirus virion.\n- The task also requires a qualitative explanation of how this stoichiometry influences capsid stability and antigenic exposure compared to Parvovirus B19.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded. The structural details provided for adenovirus (hexon trimers, $240$ copies) and Parvovirus B19 ($T=1$ capsid, $60$ subunits) are standard representations in structural virology. The number of hexon trimers, $240$, and penton bases, $12$, form the basis of the pseudo-triangulation number $T=25$ capsid architecture of human adenoviruses. The concepts of oligomerization, stoichiometry, multivalency, and lattice stability are fundamental principles in biophysics and immunology. The problem is well-posed, with a clear calculable part and a qualitative reasoning part that is standard in scientific discourse. The language is objective and precise. No contradictions, missing information for the calculation, or scientifically implausible claims are present.\n\n### Step 3: Verdict and Action\nThe problem is deemed valid and a full solution can be provided.\n\n### Solution Derivation\n\nThe problem consists of a quantitative calculation followed by a qualitative explanation grounded in biophysical principles.\n\n**Part 1: Calculation of Total Hexon Monomers**\n\nWe are given the number of hexon trimers per adenovirus virion and the number of monomers per trimer. The total number of hexon monomers is the product of these two quantities.\n\nLet $N_{\\text{trimers}}$ be the number of hexon trimers on the virion surface.\nFrom the problem statement, we have:\n$$N_{\\text{trimers}} = 240$$\n\nLet $M_{\\text{monomers/trimer}}$ be the number of monomeric subunits per hexon trimer.\nFrom the problem statement, this is:\n$$M_{\\text{monomers/trimer}} = 3$$\n\nThe total number of hexon monomers, denoted as $N_{\\text{monomers}}$, is calculated by multiplying the number of trimers by the number of monomers per trimer:\n$$N_{\\text{monomers}} = N_{\\text{trimers}} \\times M_{\\text{monomers/trimer}}$$\n$$N_{\\text{monomers}} = 240 \\times 3$$\n$$N_{\\text{monomers}} = 720$$\n\nThus, there are $720$ hexon monomers in a single adenovirus virion.\n\n**Part 2: Qualitative Comparison of Adenovirus and Parvovirus B19**\n\nThe comparison will address two aspects: capsid stability and antigenic exposure, based on first principles of multivalency and cooperative interactions in lattices.\n\n**1. Capsid Stability**\n\nThe stability of a viral capsid is a result of the cumulative non-covalent interactions (e.g., hydrophobic interactions, hydrogen bonds, salt bridges) between its constituent protein subunits. The overall stability arises from the avidity of the system, which is the compounded strength of multiple, relatively weak individual interactions.\n\n- **Adenovirus:** The capsid is constructed from a large number of subunits. The hexon components alone contribute $720$ monomers. These monomers are organized into $240$ trimers, which then assemble into a large, quasi-crystalline icosahedral lattice. The total stability of the capsid is a function of the vast network of interactions, both within each trimer (intra-trimer) and between adjacent trimers (inter-trimer). The large number of interacting partners creates a highly cooperative system. The disruption of a single bond or a few bonds is unlikely to compromise the integrity of the entire structure, as the stress is distributed over a large number of redundant contacts. This extensive networking of interactions confers high thermodynamic and mechanical stability to the adenovirus capsid.\n\n- **Parvovirus B19:** The capsid has a $T=1$ symmetry, meaning it is composed of exactly $60$ identical or chemically similar protein subunits. While these $60$ subunits are arranged to maximize contacts in an icosahedral shell, the absolute number of inter-subunit interactions is far lower than in an adenovirus. Consequently, the total binding energy stabilizing the parvovirus capsid is significantly less than that of the much larger and more complex adenovirus capsid. While perfectly stable for its biological function, its structural resilience, when compared on a whole-virion basis to adenovirus, is expected to be lower due to the smaller number of cooperative interactions.\n\n**2. Antigenic Exposure and Immune Recognition**\n\nAntigenicity depends on the chemical nature of surface-exposed epitopes and, crucially, their copy number and spatial arrangement. Immune recognition, particularly by antibodies, is highly sensitive to epitope multiplicity through the principle of multivalency.\n\n- **Adenovirus:** With $720$ hexon monomers, any epitope located on the hexon protein is present in $720$ copies on the virion surface. This creates an extremely high-density, multivalent antigenic display. An antibody molecule, such as the bivalent IgG or the pentameric IgM, can bind simultaneously to multiple identical epitopes on the viral surface. This multivalent binding leads to a dramatic increase in the overall binding strength (avidity), which is orders of magnitude greater than the intrinsic binding strength of a single antibody-binding site to a single epitope (affinity). This high-avidity interaction facilitates very efficient antibody-mediated neutralization, as the virus becomes rapidly and irreversibly coated with antibodies.\n\n- **Parvovirus B19:** With its $60$ capsid subunits, the maximum copy number for any single epitope is $60$. While this number is sufficient to permit multivalent antibody binding, the density and total number of available epitopes are substantially lower than for adenovirus. The avidity gain from multivalent binding will be less pronounced compared to the highly repetitive adenovirus surface. The geometric constraints of the smaller $T=1$ lattice might also present a different spatial pattern of epitopes, potentially affecting the efficiency of simultaneous binding by a single antibody molecule.\n\nIn summary, the higher-order stoichiometry of the adenovirus capsid ($720$ hexon monomers) compared to the simpler $T=1$ parvovirus capsid ($60$ subunits) leads to a more stable virion due to a larger network of cooperative interactions. It also results in a more potently antigenic surface due to a much higher degree of multivalency, which promotes high-avidity interactions with the host immune system.", "answer": "$$\\boxed{720}$$", "id": "4603459"}, {"introduction": "Detecting and quantifying viruses is a cornerstone of modern medical microbiology, with quantitative Polymerase Chain Reaction (qPCR) being a primary tool. This practice challenges you to work from the first principles of exponential amplification to understand the relationship between a sample's initial viral load, represented as $N_{0}$, and the resulting cycle threshold ($C_t$) value. Mastering this concept is essential for correctly interpreting qPCR data and understanding how we measure the extent of an infection [@problem_id:4603476].", "problem": "In a clinical laboratory studying respiratory pathogens, two patient plasma samples are tested by quantitative Polymerase Chain Reaction (qPCR) assays: one targeting the adenovirus hexon gene and another targeting the Parvovirus B19 nonstructural protein 1 (NS1) gene. For qPCR, the cycle threshold (Ct) is defined as the number of amplification cycles at which the fluorescence signal crosses a fixed detection threshold. Consider the foundational amplification model of Polymerase Chain Reaction (PCR): if the per-cycle amplification efficiency is $E$ (where $0 \\leq E \\leq 1$), then the per-cycle multiplication factor is $r = 1 + E$, and the amplicon copy number after $c$ cycles is given by $N(c) = N_{0}r^{c}$, where $N_{0}$ is the initial template copy number. The Ct is the smallest $c$ such that $N(c)$ reaches a fixed threshold $N_{\\mathrm{th}}$, which is identical across samples run on the same instrument for the same target. Using these definitions and the exponential growth model, explain how amplification efficiency $E$ governs the relationship between Ct and $N_{0}$, and derive, from first principles, how a difference in cycle thresholds $\\Delta \\mathrm{Ct}$ between two samples determines the ratio of their initial template quantities.\n\nThen, assuming $100\\%$ amplification efficiency (that is, $E = 1$ so $r = 2$) for a validated Parvovirus B19 NS1 qPCR assay over the relevant dynamic range, two samples yield a cycle threshold difference of $\\Delta \\mathrm{Ct} = 3.3$ (defined as $\\Delta \\mathrm{Ct} = \\mathrm{Ct}_{\\mathrm{B}} - \\mathrm{Ct}_{\\mathrm{A}}$, where sample A has the lower Ct). Calculate the fold difference in initial viral loads between sample A and sample B implied by this $\\Delta \\mathrm{Ct}$ under $100\\%$ efficiency. Round your final fold-difference to three significant figures and express it as a unitless decimal.", "solution": "The problem statement is evaluated as scientifically grounded, well-posed, and objective. It is based on the standard exponential model of Polymerase Chain Reaction (PCR) amplification, a cornerstone of quantitative molecular biology. The definitions provided for amplification efficiency, cycle threshold, and initial template quantity are standard and internally consistent. The data supplied for the calculation are physically realistic. Therefore, the problem is deemed valid and a full solution is warranted.\n\nThe solution proceeds in two parts as requested: first, a derivation of the general relationships, and second, a specific calculation.\n\n**Part 1: Derivation of General Relationships**\n\nThe starting point is the exponential amplification model for PCR, which describes the number of amplicon copies, $N(c)$, after $c$ cycles of reaction:\n$$\nN(c) = N_{0} \\, r^{c}\n$$\nHere, $N_0$ is the initial number of template molecules, and $r$ is the per-cycle multiplication factor. The factor $r$ is related to the amplification efficiency, $E$, by the definition $r = 1 + E$. The efficiency $E$ represents the fraction of templates that are successfully replicated in one cycle. An ideal, $100\\%$ efficient reaction corresponds to $E=1$, where every template is duplicated, yielding $r=2$. A complete failure to amplify corresponds to $E=0$, yielding $r=1$. Thus, the model can be written as:\n$$\nN(c) = N_{0} (1+E)^{c}\n$$\nThe cycle threshold, denoted $\\mathrm{Ct}$, is defined as the cycle number at which the fluorescence signal, which is proportional to the amount of amplified DNA, crosses a predetermined fixed threshold. In terms of amplicon copy number, this means that at $c = \\mathrm{Ct}$, the number of copies $N(c)$ reaches a threshold value $N_{\\mathrm{th}}$. We treat $\\mathrm{Ct}$ as a continuous variable for this derivation, which is a standard and valid approximation.\n$$\nN_{\\mathrm{th}} = N(\\mathrm{Ct}) = N_{0} (1+E)^{\\mathrm{Ct}}\n$$\nTo understand how the amplification efficiency $E$ governs the relationship between $\\mathrm{Ct}$ and $N_0$, we can rearrange this equation to solve for $\\mathrm{Ct}$. Taking the natural logarithm of both sides:\n$$\n\\ln(N_{\\mathrm{th}}) = \\ln(N_{0} (1+E)^{\\mathrm{Ct}}) = \\ln(N_{0}) + \\ln((1+E)^{\\mathrm{Ct}})\n$$\n$$\n\\ln(N_{\\mathrm{th}}) = \\ln(N_{0}) + \\mathrm{Ct} \\ln(1+E)\n$$\nIsolating $\\mathrm{Ct}$ gives the explicit relationship:\n$$\n\\mathrm{Ct} = \\frac{\\ln(N_{\\mathrm{th}}) - \\ln(N_{0})}{\\ln(1+E)} = \\frac{\\ln(N_{\\mathrm{th}}/N_{0})}{\\ln(1+E)}\n$$\nThis equation reveals that $\\mathrm{Ct}$ is inversely proportional to $\\ln(1+E)$ and linearly related to $-\\ln(N_{0})$. The amplification efficiency $E$ determines the base of the exponential growth. A lower efficiency (smaller $E$) leads to a smaller value of $\\ln(1+E)$, which in turn increases the $\\mathrm{Ct}$ value for a given $N_0$ and $N_{\\mathrm{th}}$. In a plot of $\\mathrm{Ct}$ versus $\\log(N_0)$, the slope of the line is $-1/\\ln(1+E)$. Therefore, the efficiency $E$ directly dictates the sensitivity of the assay and the spacing of $\\mathrm{Ct}$ values for different initial concentrations.\n\nNext, we derive how a difference in cycle thresholds, $\\Delta \\mathrm{Ct}$, determines the ratio of initial template quantities. Consider two samples, A and B, analyzed with the same qPCR assay. This implies that the amplification efficiency $E$ and the detection threshold $N_{\\mathrm{th}}$ are identical for both. The initial template quantities are $N_{0, \\mathrm{A}}$ and $N_{0, \\mathrm{B}}$, and the corresponding cycle thresholds are $\\mathrm{Ct}_{\\mathrm{A}}$ and $\\mathrm{Ct}_{\\mathrm{B}}$.\n\nFor sample A:\n$$\nN_{\\mathrm{th}} = N_{0, \\mathrm{A}} (1+E)^{\\mathrm{Ct}_{\\mathrm{A}}}\n$$\nFor sample B:\n$$\nN_{\\mathrm{th}} = N_{0, \\mathrm{B}} (1+E)^{\\mathrm{Ct}_{\\mathrm{B}}}\n$$\nSince $N_{\\mathrm{th}}$ is the same for both, we can set the two expressions equal to each other:\n$$\nN_{0, \\mathrm{A}} (1+E)^{\\mathrm{Ct}_{\\mathrm{A}}} = N_{0, \\mathrm{B}} (1+E)^{\\mathrm{Ct}_{\\mathrm{B}}}\n$$\nTo find the ratio of their initial template quantities, we rearrange the equation:\n$$\n\\frac{N_{0, \\mathrm{A}}}{N_{0, \\mathrm{B}}} = \\frac{(1+E)^{\\mathrm{Ct}_{\\mathrm{B}}}}{(1+E)^{\\mathrm{Ct}_{\\mathrm{A}}}}\n$$\nUsing the property of exponents, $x^a / x^b = x^{a-b}$, we get:\n$$\n\\frac{N_{0, \\mathrm{A}}}{N_{0, \\mathrm{B}}} = (1+E)^{\\mathrm{Ct}_{\\mathrm{B}} - \\mathrm{Ct}_{\\mathrm{A}}}\n$$\nDefining the difference in cycle thresholds as $\\Delta \\mathrm{Ct} = \\mathrm{Ct}_{\\mathrm{B}} - \\mathrm{Ct}_{\\mathrm{A}}$, the relationship is:\n$$\n\\frac{N_{0, \\mathrm{A}}}{N_{0, \\mathrm{B}}} = (1+E)^{\\Delta \\mathrm{Ct}}\n$$\nThis fundamental equation of relative quantification in qPCR shows that the ratio of initial template concentrations is an exponential function of the difference in cycle thresholds.\n\n**Part 2: Specific Calculation**\n\nWe are given the following for a Parvovirus B19 NS1 qPCR assay:\n- Amplification efficiency is $100\\%$, so $E=1$. This implies the per-cycle multiplication factor is $r = 1+E = 1+1 = 2$.\n- The difference in cycle thresholds between two samples is $\\Delta \\mathrm{Ct} = \\mathrm{Ct}_{\\mathrm{B}} - \\mathrm{Ct}_{\\mathrm{A}} = 3.3$.\n- Sample A has a lower $\\mathrm{Ct}$ value than sample B, which means sample A has a higher initial viral load ($N_{0, \\mathrm{A}} > N_{0, \\mathrm{B}}$).\n\nThe question asks for the fold difference in initial viral loads between sample A and sample B. This is the ratio of the higher concentration to the lower concentration, which is $N_{0, \\mathrm{A}} / N_{0, \\mathrm{B}}$.\n\nUsing the derived formula with the given values:\n$$\n\\frac{N_{0, \\mathrm{A}}}{N_{0, \\mathrm{B}}} = (1+E)^{\\Delta \\mathrm{Ct}} = (1+1)^{3.3} = 2^{3.3}\n$$\nWe now calculate the numerical value of $2^{3.3}$:\n$$\n2^{3.3} = 2^{3} \\times 2^{0.3} = 8 \\times 2^{0.3}\n$$\nThe value is calculated as:\n$$\n2^{3.3} \\approx 9.84738...\n$$\nThe problem requires the final answer to be rounded to three significant figures.\n$$\n\\frac{N_{0, \\mathrm{A}}}{N_{0, \\mathrm{B}}} \\approx 9.85\n$$\nThus, sample A has approximately $9.85$ times the initial viral load of sample B.", "answer": "$$\\boxed{9.85}$$", "id": "4603476"}, {"introduction": "Clinical diagnosis is rarely a simple case of a single test giving a definitive answer; it is a process of weighing evidence under uncertainty. This problem places you in the role of a clinician faced with ambiguous symptoms and multiple possible causes. By applying the principles of Bayesian probability, you will practice how to formally combine pre-test clinical suspicion with the results of imperfect diagnostic tests to calculate a more accurate, evidence-based post-test probability, a core skill in modern medicine [@problem_id:4603475].", "problem": "A febrile adult presents with conjunctival injection and symmetric small-joint arthralgia. After history and examination, the clinician narrows the differential to two mutually exclusive and exhaustive etiologies for the current illness: adenoviral keratoconjunctivitis (hypothesis $\\mathrm{A}$) and Parvovirus B19 arthropathy (hypothesis $\\mathrm{B}$). Based on epidemiology and clinical features, the clinician assigns pre-test probabilities within this restricted differential of $P(\\mathrm{A}) = 0.60$ and $P(\\mathrm{B}) = 0.40$. Two targeted assays are ordered:\n- A conjunctival swab Adenovirus polymerase chain reaction (PCR) with sensitivity $0.92$ and specificity $0.98$ for adenoviral keratoconjunctivitis.\n- A serum Parvovirus B19 immunoglobulin M (IgM) enzyme immunoassay with sensitivity $0.85$ and specificity $0.95$ for acute Parvovirus B19 infection.\n\nBoth tests return positive results. Using only fundamental definitions from probability theory and diagnostic test performance (sensitivity, specificity, and conditional probability), and assuming that exactly one of $\\mathrm{A}$ or $\\mathrm{B}$ is the true etiology and that, conditional on the true etiology, the two test outcomes are independent, compute the posterior probability that the illness is due to adenoviral keratoconjunctivitis given these results.\n\nReport your answer as a single decimal number and round to four significant figures. Do not use a percent sign.", "solution": "The problem statement has been validated and is determined to be sound, well-posed, and scientifically grounded. It presents a classic Bayesian inference scenario in medical diagnostics, with all necessary data and assumptions provided. We may proceed with the solution.\n\nLet $\\mathrm{A}$ be the event that the patient has adenoviral keratoconjunctivitis, and let $\\mathrm{B}$ be the event that the patient has Parvovirus B19 arthropathy. The problem states that these two hypotheses are mutually exclusive and exhaustive, which means they form a partition of the event space. The prior probabilities are given as:\n$$P(\\mathrm{A}) = 0.60$$\n$$P(\\mathrm{B}) = 0.40$$\nNote that $P(\\mathrm{A}) + P(\\mathrm{B}) = 0.60 + 0.40 = 1.00$, consistent with the exhaustive condition.\n\nLet $T_A^+$ be the event that the Adenovirus PCR test is positive, and let $T_B^+$ be the event that the Parvovirus B19 IgM test is positive. The evidence, $E$, is that both tests returned positive results. Therefore, $E = T_A^+ \\cap T_B^+$.\n\nWe are asked to compute the posterior probability of hypothesis $\\mathrm{A}$ given the evidence $E$, which is denoted as $P(\\mathrm{A}|E)$. We will use Bayes' theorem:\n$$P(\\mathrm{A}|E) = \\frac{P(E|\\mathrm{A}) P(\\mathrm{A})}{P(E)}$$\n\nThe denominator, $P(E)$, is the total probability of observing the evidence. It can be calculated using the law of total probability, marginalizing over the partition $\\{\\mathrm{A}, \\mathrm{B}\\}$:\n$$P(E) = P(E|\\mathrm{A})P(\\mathrm{A}) + P(E|\\mathrm{B})P(\\mathrm{B})$$\n\nSubstituting this into Bayes' theorem gives the full expression:\n$$P(\\mathrm{A}|E) = \\frac{P(E|\\mathrm{A}) P(\\mathrm{A})}{P(E|\\mathrm{A})P(\\mathrm{A}) + P(E|\\mathrm{B})P(\\mathrm{B})}$$\n\nThe next step is to determine the likelihoods, $P(E|\\mathrm{A})$ and $P(E|\\mathrm{B})$. The problem states that, conditional on the true etiology, the two test outcomes are independent. This assumption is crucial.\nTherefore, the likelihood of observing both positive tests given that the true disease is $\\mathrm{A}$ is:\n$$P(E|\\mathrm{A}) = P(T_A^+ \\cap T_B^+ | \\mathrm{A}) = P(T_A^+|\\mathrm{A}) \\times P(T_B^+|\\mathrm{A})$$\nAnd the likelihood given that the true disease is $\\mathrm{B}$ is:\n$$P(E|\\mathrm{B}) = P(T_A^+ \\cap T_B^+ | \\mathrm{B}) = P(T_A^+|\\mathrm{B}) \\times P(T_B^+|\\mathrm{B})$$\n\nWe now must extract the conditional probabilities for each test from the provided sensitivity and specificity data.\nFor the Adenovirus PCR test:\nThe sensitivity for adenoviral keratoconjunctivitis ($\\mathrm{A}$) is the probability of a positive test given disease $\\mathrm{A}$:\n$$P(T_A^+|\\mathrm{A}) = 0.92$$\nThe specificity is the probability of a negative test given no disease $\\mathrm{A}$. In our partition, \"no $\\mathrm{A}$\" is equivalent to \"$\\mathrm{B}$\". So, the specificity is $P(T_A^-|\\mathrm{B}) = 0.98$. The probability of a false positive for this test is:\n$$P(T_A^+|\\mathrm{B}) = 1 - P(T_A^-|\\mathrm{B}) = 1 - 0.98 = 0.02$$\n\nFor the Parvovirus B19 IgM test:\nThe sensitivity for Parvovirus B19 ($\\mathrm{B}$) is the probability of a positive test given disease $\\mathrm{B}$:\n$$P(T_B^+|\\mathrm{B}) = 0.85$$\nThe specificity is the probability of a negative test given no disease $\\mathrm{B}$. In our partition, \"no $\\mathrm{B}$\" is equivalent to \"$\\mathrm{A}$\". So, the specificity is $P(T_B^-|\\mathrm{A}) = 0.95$. The probability of a false positive for this test is:\n$$P(T_B^+|\\mathrm{A}) = 1 - P(T_B^-|\\mathrm{A}) = 1 - 0.95 = 0.05$$\n\nNow we can compute the likelihoods $P(E|\\mathrm{A})$ and $P(E|\\mathrm{B})$:\n$$P(E|\\mathrm{A}) = P(T_A^+|\\mathrm{A}) \\times P(T_B^+|\\mathrm{A}) = 0.92 \\times 0.05 = 0.046$$\n$$P(E|\\mathrm{B}) = P(T_A^+|\\mathrm{B}) \\times P(T_B^+|\\mathrm{B}) = 0.02 \\times 0.85 = 0.017$$\n\nWe have all the components needed to calculate the posterior probability $P(\\mathrm{A}|E)$.\nThe numerator of Bayes' theorem is:\n$$P(E|\\mathrm{A})P(\\mathrm{A}) = 0.046 \\times 0.60 = 0.0276$$\nThe term for hypothesis $\\mathrm{B}$ in the denominator is:\n$$P(E|\\mathrm{B})P(\\mathrm{B}) = 0.017 \\times 0.40 = 0.0068$$\nThe total probability of the evidence, $P(E)$, is the sum of these two terms:\n$$P(E) = 0.0276 + 0.0068 = 0.0344$$\nFinally, we can compute the posterior probability:\n$$P(\\mathrm{A}|E) = \\frac{P(E|\\mathrm{A})P(\\mathrm{A})}{P(E)} = \\frac{0.0276}{0.0344}$$\nCalculating the final value:\n$$P(\\mathrm{A}|E) = \\frac{0.0276}{0.0344} = \\frac{276}{344} = \\frac{69}{86} \\approx 0.80232558...$$\n\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $8$, $0$, $2$, and $3$. The fifth digit is $2$, so we round down.\n$$P(\\mathrm{A}|E) \\approx 0.8023$$", "answer": "$$\\boxed{0.8023}$$", "id": "4603475"}]}